These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

738 related items for PubMed ID: 9553667

  • 1. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M, van den Berg HW, Lynch M.
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase.
    El-Zarruk AA, van den Berg HW.
    Cancer Lett; 1999 Aug 03; 142(2):185-93. PubMed ID: 10463775
    [Abstract] [Full Text] [Related]

  • 5. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
    van den Berg HW, Martin J, Lynch M.
    Br J Cancer; 1990 Apr 03; 61(4):504-7. PubMed ID: 2139575
    [Abstract] [Full Text] [Related]

  • 6. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
    Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI.
    Breast Cancer Res Treat; 2003 Sep 03; 81(1):81-93. PubMed ID: 14531500
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro.
    McCotter D, van den Berg HW, Boylan M, McKibben B.
    Cancer Lett; 1996 Feb 06; 99(2):239-45. PubMed ID: 8616830
    [Abstract] [Full Text] [Related]

  • 10. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
    Herman ME, Katzenellenbogen BS.
    J Steroid Biochem Mol Biol; 1996 Oct 06; 59(2):121-34. PubMed ID: 9010327
    [Abstract] [Full Text] [Related]

  • 11. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
    Anticancer Res; 2006 Oct 06; 26(3A):1773-84. PubMed ID: 16827106
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
    Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K.
    J Steroid Biochem Mol Biol; 2003 May 06; 85(1):33-47. PubMed ID: 12798355
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.
    Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE, Westley BR.
    Eur J Cancer; 1993 May 06; 29A(16):2256-64. PubMed ID: 8110496
    [Abstract] [Full Text] [Related]

  • 16. Suramin-induced growth inhibition and insulin-like growth factor-I binding blockade in human breast carcinoma cell lines: potentially related events.
    Ravera F, Miglietta L, Pirani P, Ferrini S, Favoni RE.
    Eur J Cancer; 1993 May 06; 29A(2):225-30. PubMed ID: 8422287
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
    Stone A, Valdés-Mora F, Gee JM, Farrow L, McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL, Musgrove EA, Nicholson RI.
    PLoS One; 2012 May 06; 7(7):e40466. PubMed ID: 22808167
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.
    Lykkesfeldt AE, Larsen SS, Briand P.
    Int J Cancer; 1995 May 16; 61(4):529-34. PubMed ID: 7759159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.